Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1224 • 2018 ACR/ARHP Annual Meeting
High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment
Konstantinos Thomas¹, Anastasia Makris¹, Christina Tsalapaki¹, Argyro Lazarini¹, Kalliopi Klavdianou¹, Katerina Antonatou¹, Christos Koutsianas¹, Chrisoula Hatzara¹, Emilia Hadziyannis¹ and Dimitrios Vassilopoulos², ¹Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ²Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General HospitalMedicine, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Background/Purpose: Baseline screening for tuberculosis (TB) with tuberculin skin testing (TST) and/or interferon-gamma release assays (IGRAs) is recommended for all rheumatic patients starting biologic DMARDs…
Abstract Number: 2595 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Valeria Biermann⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Nürnberg, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various clinical trials. Data from socio- and health economic parameters and costs in daily clinical…
Abstract Number: 1517 • 2018 ACR/ARHP Annual Meeting
Integrated Safety Analysis across Phase 3 Clinical Studies Including the Controlled and Uncontrolled Periods for Intravenous Golimumab in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Arthur Kavanaugh¹, Atul A. Deodhar², Sergio Schwartzman³, Shelly Kafka⁴, Soumya D Chakravarty⁵, Elizabeth C Hsia⁶, Diane D. Harrison⁷, Jocelyn Leu⁷, Yiying Zhou⁷, Kim Hung Lo⁷ and M. Elaine Husni⁸, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Oregon Health & Science U, Portland, OR, ³Weill Cornell Medical College, New York, NY, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁶Janssen Reseach & Development, LLC/ U of Pennsylvania School of Medicine, Spring House/Philadelphia, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH
Background/Purpose: The GO-FURTHER, GO-VIBRANT, and GO-ALIVE randomized controlled trials evaluated the efficacy and safety of intravenous (IV) golimumab (GLM) in patients (pts) with active rheumatoid…
Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Madeline J. Epsten¹, Lisa A. Mandl¹, Jackie Szymonifka² and Sergio Schwartzman¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…
Abstract Number: 1591 • 2018 ACR/ARHP Annual Meeting
Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis?
Lihi Eder¹, Chandra Farrer² and Dana Jerome³, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Rheumatology, Women's College Hospital, Toronto, ON, Canada, ³University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is a key feature in psoriatic arthritis (PsA) affecting approximately a third of the patients. Ultrasound improves the detection of enthesitis compared to…
Abstract Number: 2831 • 2018 ACR/ARHP Annual Meeting
High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Thomas Renson³, Roos Colman⁴, Dirk Elewaut⁵ and Filip van Den Bosch⁶, ¹Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Ghent, 9000, Belgium, ⁴Department of Public Health, Ghent University, Ghent, Belgium, Biostatistics Unit,Ghent University, Ghent, Belgium, Ghent, Belgium, ⁵Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ⁶Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium
Background/Purpose: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease.…
Abstract Number: 1604 • 2018 ACR/ARHP Annual Meeting
Impact of Time to Minimal Disease Activity and Quality of Life One Year after Diagnosis of Psoriatic Arthritis
Kim Wervers¹, Jolanda J. Luime¹, Ilja Tchetverikov², Andreas H. Gerards³, M.R. Kok⁴, Cathelijne W. Y. Appels⁵, Wiebo L. van der Graaff⁶, Johannes H. L. M. van Groenendael⁷, Lindy-Anne Korswagen³, Josien J Veris-van Dieren⁸, JMW Hazes¹ and Marijn Vis¹, ¹Erasmus Medical Centre, Rotterdam, Netherlands, ²Albert Schweitzer Hospital, Dordrecht, Netherlands, ³Sint Franciscus Vlietland Group, Rotterdam, Netherlands, ⁴Rheumatology, Maasstad Ziekenhuis, Rotterdam, Netherlands, ⁵Rheumatology, Amphia Hospital, Breda, Netherlands, ⁶Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁷Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands
Background/Purpose: From previous cross-sectional research we know that minimal disease activity (MDA) is associated with better health-related quality of life (HRQoL) in psoriatic arthritis (PsA).…
Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
Ralf G. Thiele¹, Yahui Grace Chiu², Nelson Huertas³, Dongge Li⁴, Changyong Feng⁵, Sharon Moorehead⁶, Cristy Bell⁷ and Christopher T. Ritchlin⁸, ¹Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY
Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…
Abstract Number: 1608 • 2018 ACR/ARHP Annual Meeting
The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease
Curtis Sobchak¹, Shadi Akhtari², Paula Harvey², Dafna D Gladman³, Vinod Chandran⁴, Richard J. Cook⁵ and Lihi Eder⁶, ¹Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ⁵Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁶Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Patients with psoriatic disease (PsD) are at a high risk of developing cardiovascular events (CVE). The performance of clinical algorithms for cardiovascular risk stratification,…
Abstract Number: 1611 • 2018 ACR/ARHP Annual Meeting
Hospitalizations for Serious Infections in Psoriatic Arthritis Patients: Data from the National Inpatient Sample 2000-2014
Paras Karmacharya¹, Cynthia S. Crowson², Dilli Poudel³, Pragya Shrestha⁴ and Kerry Wright⁵, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Internal Medicine, Reading Hospital-Tower Health System, WEST READING, PA, ⁴Internal medicine, Reading Hospital-Tower Health System, West Reading, PA, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Increased risk of infections has been recognized in patients with psoriatic arthritis (PsA) compared to those without PsA. Immunomodulatory effects of PsA, immunosuppressive therapies…
Abstract Number: 1637 • 2018 ACR/ARHP Annual Meeting
Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis
Saad Ullah Malik¹, Kinza Muzaffar², Jawad Bilal³, Warda Faridi⁴ and Salman Muddassir⁵, ¹University of Arizona, Tucson, AZ, ²Internal medicine, Oak Hill Hospital,affiliated with USF, spring hill, FL, ³Internal Medicine, University of Arizona, Tucson, AZ, ⁴Department of Hematology/Oncology, University of Arizona, Tucson, AZ, ⁵Oakhill Hospital, Brookesville, FL
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory condition of peripheral joints. If left untreated, it can lead to significant pain and joint deformity. Its treatment…
Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting
Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Philip J Mease¹, Joel Kremer², Stanley Cohen³, Jeffrey R Curtis⁴, Christina Charles-Schoeman⁵, Edward V Loftus⁶, Jeffrey D Greenberg⁷, Niki Palmetto⁸, Keith S Kanik⁹, Daniela Graham⁹, Cunshan Wang⁹, Pinaki Biswas⁸, Gary Chan¹⁰, Ryan DeMasi¹⁰, Hernan Valdez⁸, Thijs Hendrikx¹⁰ and Thomas V Jones¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ³Metroplex Clinical Research Center, Dallas, TX, ⁴University of Alabama, Birmingham, AL, ⁵University of California, Los Angeles, CA, ⁶Mayo Clinic, Rochester, MN, ⁷Corrona, LLC, Southborough, MA, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
Abstract Number: 601 • 2017 ACR/ARHP Annual Meeting
Long-Term (4-Year) Efficacy and Safety of Apremilast Monotherapy in DMARD-Naive Subjects with Active Psoriatic Arthritis
Alvin F. Wells¹, Christopher J. Edwards², Alan J. Kivitz³, Paul Bird⁴, Dianne Nguyen⁵, Maria Paris⁵, Lichen Teng⁵ and Jacob A. Aelion⁶, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University Hospital Southampton, Southampton, United Kingdom, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴University Of New South Wales, Sydney, Australia, ⁵Celgene Corporation, Summit, NJ, ⁶West Tennessee Research Institute, Jackson, TN
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune responses that cause joint inflammation and other manifestations of psoriatic arthritis…
Abstract Number: 887 • 2017 ACR/ARHP Annual Meeting
A Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose, Safety, and Pharmacokinetics Study of CC-220 in Subjects with Systemic LUPUS Erythematosus
Richard Furie¹, Victoria P. Werth², Allison Gaudy³, Ying Ye³, Shimon Korish³, Ada Azaryan³, Nikolay Delev³, Douglas Hough³, Michael Weiswasser³, Suktae Choi³ and Peter Schafer³, ¹Northwell Health, Great Neck, NY, ²University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ³Celgene Corporation, Summit, NJ
Background/Purpose: CC-220 is a CUL4CRBN E3 ubiquitin ligase modulator that binds to cereblon and leads to potent and deep reduction of the transcription factors Ikaros(IKZF1)…
Abstract Number: 2555 • 2017 ACR/ARHP Annual Meeting
Clinical History of Psoriatic Arthritis over Four Decades
Dafna D Gladman¹, Justine Y. Ye² and Vinod Chandran³, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Medicine, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease associated with psoriasis. Over the past several decades it was recognized that PsA is more common…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].